MedTrace Logo

HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men

NCT06498531 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2025-06-13

No results posted yet for this study

Summary

Randomized clinical trial evaluating the effect of acetazolamide on sleep disordered breathing in women compared to men travelling to 3600 m.

Conditions

  • Sleep-Disordered Breathing

Interventions

DRUG

Acetazolamide

Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.

DRUG

Placebo

Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University Hospital Heidelberg

    collaborator OTHER

  • Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Michael Furian, Prof. Dr. · University of Zurich

  • Talant Sooronbaev, Prof. Dr. · National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06498531 on ClinicalTrials.gov